• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Science . Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

tetano

Editor, Senior Moderator
Science


. 2021 Jan 12;eabe6230.
doi: 10.1126/science.abe6230. Online ahead of print.
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape


Paul-Albert Koenig[SUP] 1 2 [/SUP], Hrishikesh Das[SUP] #[/SUP][SUP] 3 [/SUP], Hejun Liu[SUP] #[/SUP][SUP] 4 [/SUP], Beate M K?mmerer[SUP] 5 6 [/SUP], Florian N Gohr[SUP] #[/SUP][SUP] 2 [/SUP], Lea-Marie Jenster[SUP] #[/SUP][SUP] 2 [/SUP], Lisa D J Schiffelers[SUP] #[/SUP][SUP] 2 [/SUP], Yonas M Tesfamariam[SUP] #[/SUP][SUP] 2 [/SUP], Miki Uchima[SUP] #[/SUP][SUP] 2 [/SUP], Jennifer D Wuerth[SUP] #[/SUP][SUP] 2 [/SUP], Karl Gatterdam[SUP] 7 [/SUP], Natalia Ruetalo[SUP] 8 [/SUP], Maria H Christensen[SUP] 2 [/SUP], Caroline I Fandrey[SUP] 2 [/SUP], Sabine Normann[SUP] 2 [/SUP], Jan M P T?dtmann[SUP] 9 [/SUP], Steffen Pritzl[SUP] 9 [/SUP], Leo Hanke[SUP] 10 [/SUP], Jannik Boos[SUP] 11 [/SUP], Meng Yuan[SUP] 4 [/SUP], Xueyong Zhu[SUP] 4 [/SUP], Jonathan L Schmid-Burgk[SUP] 12 [/SUP], Hiroki Kato[SUP] 13 [/SUP], Michael Schindler[SUP] 8 [/SUP], Ian A Wilson[SUP] 4 14 [/SUP], Matthias Geyer[SUP] 7 [/SUP], Kerstin U Ludwig[SUP] 11 [/SUP], B Martin H?llberg[SUP] 15 16 [/SUP], Nicholas C Wu[SUP] 17 18 19 [/SUP], Florian I Schmidt[SUP] 1 2 [/SUP]



Affiliations

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to spread with devastating consequences. For passive immunization efforts, nanobodies have size and cost advantages over conventional antibodies. Here, we generated four neutralizing nanobodies that target the receptor-binding domain of the SARS-CoV-2 spike protein. We defined two distinct binding epitopes using x-ray crystallography and cryo-electron microscopy. Based on the structures, we engineered multivalent nanobodies with more than 100-fold improved neutralizing activity than monovalent nanobodies. Biparatopic nanobody fusions suppressed the emergence of escape mutants. Several nanobody constructs neutralized through receptor-binding competition, while other monovalent and biparatopic nanobodies triggered aberrant activation of the spike fusion machinery. These premature conformational changes in the spike protein forestalled productive fusion, and rendered the virions non-infectious.
 
Back
Top Bottom